SCHEDULE: Perceptive Advisors Discloses 7.0% Stake in Tenax Therapeutics

Perceptive Advisors LLC and affiliates reported a 7.0% passive ownership stake in Tenax Therapeutics, Inc., holding 439,142 shares of common stock.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 439,142 shares of Tenax Therapeutics, Inc. Common Stock.
• This represents 7.0% of the outstanding Common Stock of Tenax Therapeutics, Inc.
• The ownership percentage is based on 6,243,575 outstanding shares as of November 11, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Mr. Edelman is the managing member of Perceptive Advisors.
• The Reporting Persons have shared voting power and shared dispositive power over all 439,142 shares.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive stake by a reputable institutional investor, which can be seen as a vote of confidence, but provides no operational or financial performance details about Tenax Therapeutics.

Positives

• A significant 7.0% stake is held by Perceptive Advisors LLC and its affiliates, a prominent institutional investor in the life sciences sector, indicating potential confidence in Tenax Therapeutics.

Future Outlook

Not applicable, as this Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

Perceptive Advisors LLC is a well-known investment firm specializing in the life sciences sector. Their investment in Tenax Therapeutics suggests the company operates within this industry, aligning with Perceptive's typical investment focus.

Stakeholder Impact

• Shareholders may view the significant stake by a prominent institutional investor as a positive signal, potentially increasing market confidence in Tenax Therapeutics.

Key Dates

Recommendation

The disclosure of a significant passive stake by a prominent life sciences investor like Perceptive Advisors suggests a degree of confidence in Tenax Therapeutics. While this filing does not provide operational or financial performance data, the presence of such an investor can be a positive signal for current shareholders, warranting a 'hold' position to observe future developments.

Keywords

Tenax Therapeutics, Perceptive Advisors, Joseph Edelman, Schedule 13G, beneficial ownership, common stock, institutional investor